Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week. Read ...

Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

Cancer drug developer Aktis Oncology announced on Thursday that it has successfully priced its upsized U.S. initial public ...

"Aktis Oncology kicks 2026 IPO cycle off with $210m target" was originally created and published by Pharmaceutical Technology ...

Startup Parabilis Medicines has raised $305 million in new funding, money that will help bring its lead drug for a variety of ...

US biotech Aktis Oncology has filed IPO documents with the Securities and Exchange Commission (SEC), in what could be the ...

TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare ...

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are ...

Understand what a "hot issue" IPO is, why it's oversubscribed, and how it attracts both long-term investors and speculators ...

Backed by Eli Lilly, Aktis Oncology's $318M IPO marks 2026's first major biotech public offering, signaling renewed investor ...